Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glosli

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
European Journal of Haematology|January 5, 2026
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main StudyMargareth C Ozelo, Matteo Luciani, Heidi Glosli, et al.
European Journal of Haematology|January 14, 2026
Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main StudyMargareth C Ozelo, Matteo Luciani, Heidi Glosli, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 24, 2025
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study GroupMarloes de Kovel, Aimée-Claire van Haaster, Manuel Carcao, et al.
Pediatric Blood & Cancer|May 5, 2026
Impact of Centres With Different Patient Volume on Diagnostic Process, Therapeutic Strategy and Outcome in Patients With Localised Rhabdomyosarcoma: A Report From the European paediatric Soft tissue sarcoma Study Group (EpSSG)Maria Carmen Affinita, Maja Cesen, Peter Mudry, et al.
Haematologica|October 9, 2025
<i>Ex vivo</i> correction of severe coagulation Factor VII deficiency in patient-derived 3D liver organoidsGiacomo Roman, Knut H Lauritzen, Sean P Harrison, et al.
Cardiovascular Engineering and Technology|March 18, 2018
Efficient Computational Modeling of Human Ventricular Activation and Its Electrocardiographic Representation: A Sensitivity StudyJonathan P Cranford, Thomas J O'Hara, Christopher T Villongco, et al.
Computer Methods in Biomechanics and Biomedical Engineering|June 6, 2013
Towards real-time simulation of cardiac electrophysiology in a human heart at high resolutionDavid F Richards, James N Glosli, Erik W Draeger, et al.
Pediatric Blood & Cancer|April 23, 2022
Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studiesTimothy Rogers, Ilaria Zanetti, Beatrice Coppadoro, et al.
The Lancet. Oncology|September 29, 2019
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trialGianni Bisogno, Gian Luca De Salvo, Christophe Bergeron, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2021
Localised rhabdomyosarcoma in infants (<12 months) and young children (12-36 months of age) treated on the EpSSG RMS 2005 studyOlga Slater, Jennifer E Gains, Anna M Kelsey, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Haematology|January 5, 2026
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main StudyMargareth C Ozelo, Matteo Luciani, Heidi Glosli, et al.
European Journal of Haematology|January 14, 2026
Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main StudyMargareth C Ozelo, Matteo Luciani, Heidi Glosli, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 24, 2025
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study GroupMarloes de Kovel, Aimée-Claire van Haaster, Manuel Carcao, et al.
Pediatric Blood & Cancer|May 5, 2026
Impact of Centres With Different Patient Volume on Diagnostic Process, Therapeutic Strategy and Outcome in Patients With Localised Rhabdomyosarcoma: A Report From the European paediatric Soft tissue sarcoma Study Group (EpSSG)Maria Carmen Affinita, Maja Cesen, Peter Mudry, et al.
Haematologica|October 9, 2025
<i>Ex vivo</i> correction of severe coagulation Factor VII deficiency in patient-derived 3D liver organoidsGiacomo Roman, Knut H Lauritzen, Sean P Harrison, et al.
Cardiovascular Engineering and Technology|March 18, 2018
Efficient Computational Modeling of Human Ventricular Activation and Its Electrocardiographic Representation: A Sensitivity StudyJonathan P Cranford, Thomas J O'Hara, Christopher T Villongco, et al.
Computer Methods in Biomechanics and Biomedical Engineering|June 6, 2013
Towards real-time simulation of cardiac electrophysiology in a human heart at high resolutionDavid F Richards, James N Glosli, Erik W Draeger, et al.
Pediatric Blood & Cancer|April 23, 2022
Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studiesTimothy Rogers, Ilaria Zanetti, Beatrice Coppadoro, et al.
The Lancet. Oncology|September 29, 2019
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trialGianni Bisogno, Gian Luca De Salvo, Christophe Bergeron, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2021
Localised rhabdomyosarcoma in infants (<12 months) and young children (12-36 months of age) treated on the EpSSG RMS 2005 studyOlga Slater, Jennifer E Gains, Anna M Kelsey, et al.
Pageof 9